B. Riley Securities Reiterates Buy on TG Therapeutics, Maintains $42 Price Target
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Mayank Mamtani has reiterated a 'Buy' rating on TG Therapeutics (NASDAQ:TGTX) and maintained a price target of $42.
July 13, 2023 | 5:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B. Riley Securities has reiterated a 'Buy' rating on TG Therapeutics, maintaining a price target of $42.
The reiteration of a 'Buy' rating by B. Riley Securities indicates a positive outlook for TG Therapeutics. The maintained price target of $42 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100